nodes	percent_of_prediction	percent_of_DWPC	metapath
Telaprevir—CYP3A4—bone cancer	0.674	1	CbGaD
Telaprevir—CTSK—Osteoclast Signaling—TNFRSF11A—bone cancer	0.0227	0.208	CbGpPWpGaD
Telaprevir—CTSK—periosteum—bone cancer	0.0173	0.134	CbGeAlD
Telaprevir—CTSK—skull—bone cancer	0.0143	0.11	CbGeAlD
Telaprevir—CTSK—leg—bone cancer	0.0138	0.107	CbGeAlD
Telaprevir—CTSK—forelimb—bone cancer	0.0137	0.106	CbGeAlD
Telaprevir—CTSK—hindlimb—bone cancer	0.0123	0.0954	CbGeAlD
Telaprevir—CTSK—cartilage tissue—bone cancer	0.0122	0.0939	CbGeAlD
Telaprevir—CTSK—appendage—bone cancer	0.0106	0.0819	CbGeAlD
Telaprevir—CTSK—RANKL/RANK Signaling Pathway—TNFRSF11A—bone cancer	0.00846	0.0773	CbGpPWpGaD
Telaprevir—ORM1—vertebral column—bone cancer	0.00752	0.0581	CbGeAlD
Telaprevir—Boceprevir—CYP3A4—bone cancer	0.00536	1	CrCbGaD
Telaprevir—ALB—Methotrexate—bone cancer	0.00531	0.313	CbGbCtD
Telaprevir—CTSS—Collagen formation—PLOD2—bone cancer	0.00497	0.0454	CbGpPWpGaD
Telaprevir—CMA1—connective tissue—bone cancer	0.00469	0.0363	CbGeAlD
Telaprevir—ABCB1—Cisplatin—bone cancer	0.00428	0.253	CbGbCtD
Telaprevir—CTSS—Assembly of collagen fibrils and other multimeric structures—LOX—bone cancer	0.0036	0.0329	CbGpPWpGaD
Telaprevir—CMA1—bone marrow—bone cancer	0.00312	0.0241	CbGeAlD
Telaprevir—CTSK—connective tissue—bone cancer	0.00302	0.0234	CbGeAlD
Telaprevir—ABCB1—Doxorubicin—bone cancer	0.00287	0.169	CbGbCtD
Telaprevir—ABCB1—Methotrexate—bone cancer	0.00278	0.164	CbGbCtD
Telaprevir—CMA1—Extracellular matrix organization—PLOD2—bone cancer	0.00271	0.0247	CbGpPWpGaD
Telaprevir—CTSS—connective tissue—bone cancer	0.00265	0.0205	CbGeAlD
Telaprevir—Proctitis—Epirubicin—bone cancer	0.00251	0.039	CcSEcCtD
Telaprevir—CTSS—Collagen formation—LOX—bone cancer	0.00245	0.0224	CbGpPWpGaD
Telaprevir—CTSK—Extracellular matrix organization—PLOD2—bone cancer	0.00241	0.022	CbGpPWpGaD
Telaprevir—CMA1—Activation of Matrix Metalloproteinases—MMP2—bone cancer	0.00232	0.0212	CbGpPWpGaD
Telaprevir—Proctitis—Doxorubicin—bone cancer	0.00232	0.0361	CcSEcCtD
Telaprevir—CTSK—tendon—bone cancer	0.00208	0.0161	CbGeAlD
Telaprevir—CTSK—Activation of Matrix Metalloproteinases—MMP2—bone cancer	0.00207	0.0189	CbGpPWpGaD
Telaprevir—CTSK—bone marrow—bone cancer	0.00201	0.0156	CbGeAlD
Telaprevir—CTSK—spinal cord—bone cancer	0.002	0.0155	CbGeAlD
Telaprevir—CTSS—Extracellular matrix organization—PLOD2—bone cancer	0.00199	0.0181	CbGpPWpGaD
Telaprevir—Retinal disorder—Methotrexate—bone cancer	0.00183	0.0285	CcSEcCtD
Telaprevir—CTSS—tendon—bone cancer	0.00182	0.0141	CbGeAlD
Telaprevir—CTSK—Collagen degradation—MMP2—bone cancer	0.00181	0.0165	CbGpPWpGaD
Telaprevir—CTSS—bone marrow—bone cancer	0.00176	0.0136	CbGeAlD
Telaprevir—CTSS—spinal cord—bone cancer	0.00176	0.0136	CbGeAlD
Telaprevir—CMA1—Activation of Matrix Metalloproteinases—MMP9—bone cancer	0.00175	0.016	CbGpPWpGaD
Telaprevir—CYP3A4—Doxorubicin—bone cancer	0.00172	0.101	CbGbCtD
Telaprevir—ABCB1—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.00165	0.0151	CbGpPWpGaD
Telaprevir—CTSK—Activation of Matrix Metalloproteinases—MMP9—bone cancer	0.00156	0.0142	CbGpPWpGaD
Telaprevir—ABCB1—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.00154	0.0141	CbGpPWpGaD
Telaprevir—ABCB1—HIF-1-alpha transcription factor network—CITED2—bone cancer	0.00154	0.0141	CbGpPWpGaD
Telaprevir—ALB—Folate Metabolism—FOLR1—bone cancer	0.0015	0.0137	CbGpPWpGaD
Telaprevir—CMA1—Metabolism of proteins—MOGS—bone cancer	0.00149	0.0136	CbGpPWpGaD
Telaprevir—Infection—Carboplatin—bone cancer	0.00144	0.0224	CcSEcCtD
Telaprevir—CTSK—Collagen degradation—MMP9—bone cancer	0.00136	0.0124	CbGpPWpGaD
Telaprevir—CMA1—Extracellular matrix organization—LOX—bone cancer	0.00134	0.0122	CbGpPWpGaD
Telaprevir—Proctalgia—Epirubicin—bone cancer	0.00131	0.0203	CcSEcCtD
Telaprevir—Hyperuricaemia—Cisplatin—bone cancer	0.00129	0.02	CcSEcCtD
Telaprevir—CTSK—Toll-Like Receptors Cascades—ATF1—bone cancer	0.00125	0.0115	CbGpPWpGaD
Telaprevir—Blood uric acid increased—Cisplatin—bone cancer	0.00122	0.0189	CcSEcCtD
Telaprevir—Proctalgia—Doxorubicin—bone cancer	0.00121	0.0188	CcSEcCtD
Telaprevir—Lymphopenia—Epirubicin—bone cancer	0.0012	0.0186	CcSEcCtD
Telaprevir—CTSK—Extracellular matrix organization—LOX—bone cancer	0.00119	0.0109	CbGpPWpGaD
Telaprevir—Anorectal discomfort—Epirubicin—bone cancer	0.00112	0.0174	CcSEcCtD
Telaprevir—Lymphopenia—Doxorubicin—bone cancer	0.00111	0.0172	CcSEcCtD
Telaprevir—ORM1—bone marrow—bone cancer	0.00105	0.00814	CbGeAlD
Telaprevir—ORM1—spinal cord—bone cancer	0.00105	0.0081	CbGeAlD
Telaprevir—CTSK—RANKL/RANK Signaling Pathway—JUN—bone cancer	0.00104	0.00948	CbGpPWpGaD
Telaprevir—Anorectal discomfort—Doxorubicin—bone cancer	0.00104	0.0161	CcSEcCtD
Telaprevir—CTSS—Toll-Like Receptors Cascades—ATF1—bone cancer	0.00103	0.00943	CbGpPWpGaD
Telaprevir—CMA1—Degradation of the extracellular matrix—MMP2—bone cancer	0.00103	0.00936	CbGpPWpGaD
Telaprevir—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00101	0.00923	CbGpPWpGaD
Telaprevir—CMA1—Extracellular matrix organization—SPARC—bone cancer	0.001	0.00915	CbGpPWpGaD
Telaprevir—CTSS—Extracellular matrix organization—LOX—bone cancer	0.000981	0.00896	CbGpPWpGaD
Telaprevir—Oral candidiasis—Epirubicin—bone cancer	0.000965	0.015	CcSEcCtD
Telaprevir—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000951	0.00869	CbGpPWpGaD
Telaprevir—Renal failure acute—Cisplatin—bone cancer	0.000939	0.0146	CcSEcCtD
Telaprevir—CTSK—Degradation of the extracellular matrix—MMP2—bone cancer	0.000914	0.00835	CbGpPWpGaD
Telaprevir—ABCB1—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.000902	0.00824	CbGpPWpGaD
Telaprevir—CTSK—Extracellular matrix organization—SPARC—bone cancer	0.000893	0.00816	CbGpPWpGaD
Telaprevir—Oral candidiasis—Doxorubicin—bone cancer	0.000893	0.0139	CcSEcCtD
Telaprevir—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000887	0.0081	CbGpPWpGaD
Telaprevir—CTSS—Assembly of collagen fibrils and other multimeric structures—MMP9—bone cancer	0.00087	0.00794	CbGpPWpGaD
Telaprevir—CMA1—Metabolism of proteins—TUBB4B—bone cancer	0.000816	0.00745	CbGpPWpGaD
Telaprevir—Blood creatinine increased—Cisplatin—bone cancer	0.000812	0.0126	CcSEcCtD
Telaprevir—CMA1—Signaling by SCF-KIT—KIT—bone cancer	0.000801	0.00731	CbGpPWpGaD
Telaprevir—Hypokalaemia—Cisplatin—bone cancer	0.000789	0.0123	CcSEcCtD
Telaprevir—CMA1—Degradation of the extracellular matrix—MMP9—bone cancer	0.000771	0.00704	CbGpPWpGaD
Telaprevir—CTSS—Degradation of the extracellular matrix—MMP2—bone cancer	0.000753	0.00687	CbGpPWpGaD
Telaprevir—CTSS—Extracellular matrix organization—SPARC—bone cancer	0.000735	0.00672	CbGpPWpGaD
Telaprevir—Hyperbilirubinaemia—Methotrexate—bone cancer	0.00072	0.0112	CcSEcCtD
Telaprevir—Hyperuricaemia—Methotrexate—bone cancer	0.000706	0.011	CcSEcCtD
Telaprevir—CMA1—Metabolism of proteins—TUBB2A—bone cancer	0.000704	0.00643	CbGpPWpGaD
Telaprevir—CTSK—Degradation of the extracellular matrix—MMP9—bone cancer	0.000687	0.00627	CbGpPWpGaD
Telaprevir—Rectal haemorrhage—Epirubicin—bone cancer	0.000679	0.0106	CcSEcCtD
Telaprevir—Hyperbilirubinaemia—Epirubicin—bone cancer	0.000674	0.0105	CcSEcCtD
Telaprevir—Blood uric acid increased—Methotrexate—bone cancer	0.000667	0.0104	CcSEcCtD
Telaprevir—Hyperuricaemia—Epirubicin—bone cancer	0.000661	0.0103	CcSEcCtD
Telaprevir—Hepatobiliary disease—Cisplatin—bone cancer	0.000632	0.00982	CcSEcCtD
Telaprevir—CMA1—Signaling by SCF-KIT—MDM2—bone cancer	0.000631	0.00576	CbGpPWpGaD
Telaprevir—Rectal haemorrhage—Doxorubicin—bone cancer	0.000628	0.00977	CcSEcCtD
Telaprevir—Blood uric acid increased—Epirubicin—bone cancer	0.000624	0.00971	CcSEcCtD
Telaprevir—Hyperbilirubinaemia—Doxorubicin—bone cancer	0.000624	0.0097	CcSEcCtD
Telaprevir—ALB—Binding and Uptake of Ligands by Scavenger Receptors—SPARC—bone cancer	0.000614	0.0056	CbGpPWpGaD
Telaprevir—Hyperuricaemia—Doxorubicin—bone cancer	0.000611	0.00951	CcSEcCtD
Telaprevir—CTSS—Collagen formation—MMP9—bone cancer	0.000592	0.00541	CbGpPWpGaD
Telaprevir—Urinary tract disorder—Cisplatin—bone cancer	0.000592	0.00921	CcSEcCtD
Telaprevir—Urethral disorder—Cisplatin—bone cancer	0.000588	0.00914	CcSEcCtD
Telaprevir—Candida infection—Epirubicin—bone cancer	0.000585	0.0091	CcSEcCtD
Telaprevir—Blood uric acid increased—Doxorubicin—bone cancer	0.000578	0.00898	CcSEcCtD
Telaprevir—CTSS—Degradation of the extracellular matrix—MMP9—bone cancer	0.000566	0.00517	CbGpPWpGaD
Telaprevir—Eye disorder—Cisplatin—bone cancer	0.00056	0.00871	CcSEcCtD
Telaprevir—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000546	0.00499	CbGpPWpGaD
Telaprevir—ABCB1—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000544	0.00497	CbGpPWpGaD
Telaprevir—Candida infection—Doxorubicin—bone cancer	0.000541	0.00842	CcSEcCtD
Telaprevir—CMA1—Signaling by SCF-KIT—MMP9—bone cancer	0.000533	0.00487	CbGpPWpGaD
Telaprevir—Malnutrition—Cisplatin—bone cancer	0.000522	0.00812	CcSEcCtD
Telaprevir—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000518	0.00473	CbGpPWpGaD
Telaprevir—Renal failure acute—Methotrexate—bone cancer	0.000515	0.00801	CcSEcCtD
Telaprevir—Eczema—Epirubicin—bone cancer	0.000495	0.0077	CcSEcCtD
Telaprevir—CMA1—Metabolism of proteins—EIF2S1—bone cancer	0.000491	0.00448	CbGpPWpGaD
Telaprevir—CTSK—Toll-Like Receptors Cascades—JUN—bone cancer	0.000489	0.00446	CbGpPWpGaD
Telaprevir—Anaemia—Cisplatin—bone cancer	0.000482	0.0075	CcSEcCtD
Telaprevir—Renal failure acute—Epirubicin—bone cancer	0.000482	0.0075	CcSEcCtD
Telaprevir—Eczema—Doxorubicin—bone cancer	0.000458	0.00713	CcSEcCtD
Telaprevir—Renal failure acute—Doxorubicin—bone cancer	0.000446	0.00694	CcSEcCtD
Telaprevir—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000441	0.00686	CcSEcCtD
Telaprevir—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000435	0.00397	CbGpPWpGaD
Telaprevir—CMA1—Signaling by SCF-KIT—EGFR—bone cancer	0.000431	0.00394	CbGpPWpGaD
Telaprevir—CMA1—Extracellular matrix organization—MMP2—bone cancer	0.00043	0.00392	CbGpPWpGaD
Telaprevir—Toxic epidermal necrolysis—Methotrexate—bone cancer	0.000428	0.00666	CcSEcCtD
Telaprevir—Infection—Cisplatin—bone cancer	0.000423	0.00658	CcSEcCtD
Telaprevir—Nervous system disorder—Cisplatin—bone cancer	0.000418	0.0065	CcSEcCtD
Telaprevir—Thrombocytopenia—Cisplatin—bone cancer	0.000417	0.00648	CcSEcCtD
Telaprevir—Blood creatinine increased—Epirubicin—bone cancer	0.000417	0.00648	CcSEcCtD
Telaprevir—Skin disorder—Cisplatin—bone cancer	0.000414	0.00643	CcSEcCtD
Telaprevir—ALB—Folate Metabolism—DHFR—bone cancer	0.00041	0.00375	CbGpPWpGaD
Telaprevir—Eosinophilia—Methotrexate—bone cancer	0.000407	0.00633	CcSEcCtD
Telaprevir—CTSK—Innate Immune System—ATF1—bone cancer	0.000406	0.00371	CbGpPWpGaD
Telaprevir—Hypokalaemia—Epirubicin—bone cancer	0.000405	0.0063	CcSEcCtD
Telaprevir—CTSS—Toll-Like Receptors Cascades—JUN—bone cancer	0.000402	0.00367	CbGpPWpGaD
Telaprevir—Toxic epidermal necrolysis—Epirubicin—bone cancer	0.000401	0.00623	CcSEcCtD
Telaprevir—Blood creatinine increased—Doxorubicin—bone cancer	0.000386	0.006	CcSEcCtD
Telaprevir—CTSK—Extracellular matrix organization—MMP2—bone cancer	0.000383	0.0035	CbGpPWpGaD
Telaprevir—Eosinophilia—Epirubicin—bone cancer	0.000381	0.00592	CcSEcCtD
Telaprevir—Hypokalaemia—Doxorubicin—bone cancer	0.000375	0.00583	CcSEcCtD
Telaprevir—Toxic epidermal necrolysis—Doxorubicin—bone cancer	0.000371	0.00577	CcSEcCtD
Telaprevir—Gastrointestinal disorder—Cisplatin—bone cancer	0.000368	0.00572	CcSEcCtD
Telaprevir—Infestation—Methotrexate—bone cancer	0.000366	0.0057	CcSEcCtD
Telaprevir—Infestation NOS—Methotrexate—bone cancer	0.000366	0.0057	CcSEcCtD
Telaprevir—Stevens-Johnson syndrome—Methotrexate—bone cancer	0.000363	0.00565	CcSEcCtD
Telaprevir—ALB—Platelet degranulation—SPARC—bone cancer	0.00036	0.00328	CbGpPWpGaD
Telaprevir—Eosinophilia—Doxorubicin—bone cancer	0.000352	0.00548	CcSEcCtD
Telaprevir—Hepatobiliary disease—Methotrexate—bone cancer	0.000347	0.00539	CcSEcCtD
Telaprevir—Infestation NOS—Epirubicin—bone cancer	0.000343	0.00533	CcSEcCtD
Telaprevir—Infestation—Epirubicin—bone cancer	0.000343	0.00533	CcSEcCtD
Telaprevir—ALB—Response to elevated platelet cytosolic Ca2+—SPARC—bone cancer	0.000343	0.00313	CbGpPWpGaD
Telaprevir—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.00034	0.00529	CcSEcCtD
Telaprevir—CTSS—Innate Immune System—ATF1—bone cancer	0.000335	0.00305	CbGpPWpGaD
Telaprevir—CMA1—Signaling Pathways—RGS1—bone cancer	0.00033	0.00302	CbGpPWpGaD
Telaprevir—CMA1—Signaling Pathways—GRM4—bone cancer	0.00033	0.00302	CbGpPWpGaD
Telaprevir—Urinary tract disorder—Methotrexate—bone cancer	0.000325	0.00505	CcSEcCtD
Telaprevir—Hepatobiliary disease—Epirubicin—bone cancer	0.000324	0.00504	CcSEcCtD
Telaprevir—CMA1—Extracellular matrix organization—MMP9—bone cancer	0.000323	0.00295	CbGpPWpGaD
Telaprevir—Urethral disorder—Methotrexate—bone cancer	0.000322	0.00501	CcSEcCtD
Telaprevir—Infestation NOS—Doxorubicin—bone cancer	0.000317	0.00493	CcSEcCtD
Telaprevir—Infestation—Doxorubicin—bone cancer	0.000317	0.00493	CcSEcCtD
Telaprevir—CTSS—Extracellular matrix organization—MMP2—bone cancer	0.000315	0.00288	CbGpPWpGaD
Telaprevir—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.000315	0.00489	CcSEcCtD
Telaprevir—ABCB1—bone marrow—bone cancer	0.000311	0.0024	CbGeAlD
Telaprevir—Erythema multiforme—Methotrexate—bone cancer	0.000311	0.00484	CcSEcCtD
Telaprevir—ABCB1—spinal cord—bone cancer	0.00031	0.00239	CbGeAlD
Telaprevir—Eye disorder—Methotrexate—bone cancer	0.000307	0.00478	CcSEcCtD
Telaprevir—Asthenia—Cisplatin—bone cancer	0.000306	0.00475	CcSEcCtD
Telaprevir—Urinary tract disorder—Epirubicin—bone cancer	0.000304	0.00473	CcSEcCtD
Telaprevir—Oedema peripheral—Epirubicin—bone cancer	0.000303	0.00472	CcSEcCtD
Telaprevir—Urethral disorder—Epirubicin—bone cancer	0.000302	0.00469	CcSEcCtD
Telaprevir—Hepatobiliary disease—Doxorubicin—bone cancer	0.0003	0.00467	CcSEcCtD
Telaprevir—Diarrhoea—Cisplatin—bone cancer	0.000291	0.00453	CcSEcCtD
Telaprevir—Erythema multiforme—Epirubicin—bone cancer	0.000291	0.00453	CcSEcCtD
Telaprevir—CTSK—Extracellular matrix organization—MMP9—bone cancer	0.000288	0.00263	CbGpPWpGaD
Telaprevir—Eye disorder—Epirubicin—bone cancer	0.000288	0.00447	CcSEcCtD
Telaprevir—CMA1—Signaling Pathways—GRM1—bone cancer	0.000287	0.00262	CbGpPWpGaD
Telaprevir—Malnutrition—Methotrexate—bone cancer	0.000286	0.00445	CcSEcCtD
Telaprevir—Urinary tract disorder—Doxorubicin—bone cancer	0.000281	0.00437	CcSEcCtD
Telaprevir—Oedema peripheral—Doxorubicin—bone cancer	0.000281	0.00436	CcSEcCtD
Telaprevir—Dysgeusia—Methotrexate—bone cancer	0.00028	0.00436	CcSEcCtD
Telaprevir—Urethral disorder—Doxorubicin—bone cancer	0.000279	0.00434	CcSEcCtD
Telaprevir—Vomiting—Cisplatin—bone cancer	0.000271	0.00421	CcSEcCtD
Telaprevir—Erythema multiforme—Doxorubicin—bone cancer	0.000269	0.00419	CcSEcCtD
Telaprevir—Rash—Cisplatin—bone cancer	0.000269	0.00418	CcSEcCtD
Telaprevir—Dermatitis—Cisplatin—bone cancer	0.000268	0.00417	CcSEcCtD
Telaprevir—Malnutrition—Epirubicin—bone cancer	0.000268	0.00417	CcSEcCtD
Telaprevir—Eye disorder—Doxorubicin—bone cancer	0.000266	0.00414	CcSEcCtD
Telaprevir—Anaemia—Methotrexate—bone cancer	0.000265	0.00412	CcSEcCtD
Telaprevir—Dysgeusia—Epirubicin—bone cancer	0.000262	0.00408	CcSEcCtD
Telaprevir—Nausea—Cisplatin—bone cancer	0.000253	0.00393	CcSEcCtD
Telaprevir—Malnutrition—Doxorubicin—bone cancer	0.000248	0.00386	CcSEcCtD
Telaprevir—Anaemia—Epirubicin—bone cancer	0.000248	0.00385	CcSEcCtD
Telaprevir—Dysgeusia—Doxorubicin—bone cancer	0.000243	0.00378	CcSEcCtD
Telaprevir—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000242	0.00377	CcSEcCtD
Telaprevir—Syncope—Epirubicin—bone cancer	0.00024	0.00374	CcSEcCtD
Telaprevir—CTSS—Extracellular matrix organization—MMP9—bone cancer	0.000237	0.00216	CbGpPWpGaD
Telaprevir—CTSK—Immune System—ATF1—bone cancer	0.000237	0.00216	CbGpPWpGaD
Telaprevir—Loss of consciousness—Epirubicin—bone cancer	0.000236	0.00366	CcSEcCtD
Telaprevir—Infection—Methotrexate—bone cancer	0.000232	0.00361	CcSEcCtD
Telaprevir—CTSK—Innate Immune System—KIT—bone cancer	0.000231	0.00211	CbGpPWpGaD
Telaprevir—CTSK—Immune System—IL3—bone cancer	0.000231	0.00211	CbGpPWpGaD
Telaprevir—Nervous system disorder—Methotrexate—bone cancer	0.000229	0.00356	CcSEcCtD
Telaprevir—Anaemia—Doxorubicin—bone cancer	0.000229	0.00356	CcSEcCtD
Telaprevir—Thrombocytopenia—Methotrexate—bone cancer	0.000229	0.00356	CcSEcCtD
Telaprevir—Skin disorder—Methotrexate—bone cancer	0.000227	0.00353	CcSEcCtD
Telaprevir—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000227	0.00352	CcSEcCtD
Telaprevir—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	0.000226	0.00206	CbGpPWpGaD
Telaprevir—Syncope—Doxorubicin—bone cancer	0.000222	0.00346	CcSEcCtD
Telaprevir—CTSK—Adaptive Immune System—KIT—bone cancer	0.000222	0.00203	CbGpPWpGaD
Telaprevir—Loss of consciousness—Doxorubicin—bone cancer	0.000218	0.00339	CcSEcCtD
Telaprevir—Infection—Epirubicin—bone cancer	0.000217	0.00338	CcSEcCtD
Telaprevir—Shock—Epirubicin—bone cancer	0.000215	0.00335	CcSEcCtD
Telaprevir—Nervous system disorder—Epirubicin—bone cancer	0.000214	0.00334	CcSEcCtD
Telaprevir—Thrombocytopenia—Epirubicin—bone cancer	0.000214	0.00333	CcSEcCtD
Telaprevir—Skin disorder—Epirubicin—bone cancer	0.000212	0.0033	CcSEcCtD
Telaprevir—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.00021	0.00326	CcSEcCtD
Telaprevir—CMA1—Signaling Pathways—SMO—bone cancer	0.000202	0.00184	CbGpPWpGaD
Telaprevir—Gastrointestinal disorder—Methotrexate—bone cancer	0.000202	0.00314	CcSEcCtD
Telaprevir—Fatigue—Methotrexate—bone cancer	0.000201	0.00313	CcSEcCtD
Telaprevir—Infection—Doxorubicin—bone cancer	0.000201	0.00313	CcSEcCtD
Telaprevir—CMA1—Metabolism of proteins—MMP2—bone cancer	0.000201	0.00183	CbGpPWpGaD
Telaprevir—Shock—Doxorubicin—bone cancer	0.000199	0.0031	CcSEcCtD
Telaprevir—Nervous system disorder—Doxorubicin—bone cancer	0.000198	0.00309	CcSEcCtD
Telaprevir—Thrombocytopenia—Doxorubicin—bone cancer	0.000198	0.00308	CcSEcCtD
Telaprevir—Skin disorder—Doxorubicin—bone cancer	0.000197	0.00306	CcSEcCtD
Telaprevir—CTSS—Immune System—ATF1—bone cancer	0.000195	0.00178	CbGpPWpGaD
Telaprevir—CTSS—Innate Immune System—KIT—bone cancer	0.00019	0.00174	CbGpPWpGaD
Telaprevir—CTSS—Immune System—IL3—bone cancer	0.00019	0.00174	CbGpPWpGaD
Telaprevir—Gastrointestinal disorder—Epirubicin—bone cancer	0.000189	0.00294	CcSEcCtD
Telaprevir—Fatigue—Epirubicin—bone cancer	0.000189	0.00293	CcSEcCtD
Telaprevir—Urticaria—Methotrexate—bone cancer	0.000186	0.00289	CcSEcCtD
Telaprevir—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.000185	0.00169	CbGpPWpGaD
Telaprevir—CMA1—Signaling Pathways—GNA11—bone cancer	0.000185	0.00169	CbGpPWpGaD
Telaprevir—CTSS—Adaptive Immune System—KIT—bone cancer	0.000183	0.00167	CbGpPWpGaD
Telaprevir—CTSK—Innate Immune System—MDM2—bone cancer	0.000182	0.00166	CbGpPWpGaD
Telaprevir—CTSK—Adaptive Immune System—MDM2—bone cancer	0.000175	0.0016	CbGpPWpGaD
Telaprevir—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000175	0.00272	CcSEcCtD
Telaprevir—Fatigue—Doxorubicin—bone cancer	0.000174	0.00271	CcSEcCtD
Telaprevir—Urticaria—Epirubicin—bone cancer	0.000174	0.0027	CcSEcCtD
Telaprevir—CMA1—Signaling Pathways—ATF1—bone cancer	0.000172	0.00157	CbGpPWpGaD
Telaprevir—Asthenia—Methotrexate—bone cancer	0.000168	0.00261	CcSEcCtD
Telaprevir—CMA1—Signaling Pathways—IL3—bone cancer	0.000167	0.00153	CbGpPWpGaD
Telaprevir—Pruritus—Methotrexate—bone cancer	0.000165	0.00257	CcSEcCtD
Telaprevir—Urticaria—Doxorubicin—bone cancer	0.000161	0.0025	CcSEcCtD
Telaprevir—Diarrhoea—Methotrexate—bone cancer	0.00016	0.00249	CcSEcCtD
Telaprevir—ALB—Platelet activation, signaling and aggregation—SPARC—bone cancer	0.000159	0.00146	CbGpPWpGaD
Telaprevir—CTSK—Innate Immune System—JUN—bone cancer	0.000158	0.00145	CbGpPWpGaD
Telaprevir—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.000157	0.00143	CbGpPWpGaD
Telaprevir—Asthenia—Epirubicin—bone cancer	0.000157	0.00244	CcSEcCtD
Telaprevir—Pruritus—Epirubicin—bone cancer	0.000155	0.00241	CcSEcCtD
Telaprevir—Dizziness—Methotrexate—bone cancer	0.000155	0.0024	CcSEcCtD
Telaprevir—CTSS—Innate Immune System—MDM2—bone cancer	0.00015	0.00137	CbGpPWpGaD
Telaprevir—Diarrhoea—Epirubicin—bone cancer	0.00015	0.00233	CcSEcCtD
Telaprevir—Vomiting—Methotrexate—bone cancer	0.000149	0.00231	CcSEcCtD
Telaprevir—Rash—Methotrexate—bone cancer	0.000147	0.00229	CcSEcCtD
Telaprevir—Dermatitis—Methotrexate—bone cancer	0.000147	0.00229	CcSEcCtD
Telaprevir—ALB—Platelet activation, signaling and aggregation—GNA11—bone cancer	0.000146	0.00133	CbGpPWpGaD
Telaprevir—Asthenia—Doxorubicin—bone cancer	0.000145	0.00226	CcSEcCtD
Telaprevir—Dizziness—Epirubicin—bone cancer	0.000145	0.00225	CcSEcCtD
Telaprevir—CTSS—Adaptive Immune System—MDM2—bone cancer	0.000144	0.00131	CbGpPWpGaD
Telaprevir—Pruritus—Doxorubicin—bone cancer	0.000143	0.00223	CcSEcCtD
Telaprevir—CMA1—Signaling Pathways—TGFBR2—bone cancer	0.000143	0.00131	CbGpPWpGaD
Telaprevir—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.000143	0.00131	CbGpPWpGaD
Telaprevir—Vomiting—Epirubicin—bone cancer	0.000139	0.00216	CcSEcCtD
Telaprevir—Nausea—Methotrexate—bone cancer	0.000139	0.00216	CcSEcCtD
Telaprevir—Diarrhoea—Doxorubicin—bone cancer	0.000138	0.00215	CcSEcCtD
Telaprevir—Rash—Epirubicin—bone cancer	0.000138	0.00214	CcSEcCtD
Telaprevir—Dermatitis—Epirubicin—bone cancer	0.000138	0.00214	CcSEcCtD
Telaprevir—CMA1—Signaling Pathways—IGF1R—bone cancer	0.000135	0.00123	CbGpPWpGaD
Telaprevir—CTSK—Immune System—KIT—bone cancer	0.000135	0.00123	CbGpPWpGaD
Telaprevir—Dizziness—Doxorubicin—bone cancer	0.000134	0.00208	CcSEcCtD
Telaprevir—ALB—Platelet activation, signaling and aggregation—IL3—bone cancer	0.000132	0.00121	CbGpPWpGaD
Telaprevir—CTSS—Innate Immune System—JUN—bone cancer	0.00013	0.00119	CbGpPWpGaD
Telaprevir—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.00013	0.00119	CbGpPWpGaD
Telaprevir—Nausea—Epirubicin—bone cancer	0.00013	0.00202	CcSEcCtD
Telaprevir—Vomiting—Doxorubicin—bone cancer	0.000129	0.002	CcSEcCtD
Telaprevir—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	0.000128	0.00117	CbGpPWpGaD
Telaprevir—Rash—Doxorubicin—bone cancer	0.000128	0.00198	CcSEcCtD
Telaprevir—Dermatitis—Doxorubicin—bone cancer	0.000127	0.00198	CcSEcCtD
Telaprevir—CTSK—Innate Immune System—EGFR—bone cancer	0.000124	0.00114	CbGpPWpGaD
Telaprevir—ALB—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000124	0.00113	CbGpPWpGaD
Telaprevir—ALB—Selenium Micronutrient Network—PTGS2—bone cancer	0.000122	0.00112	CbGpPWpGaD
Telaprevir—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	0.000122	0.00111	CbGpPWpGaD
Telaprevir—Nausea—Doxorubicin—bone cancer	0.00012	0.00187	CcSEcCtD
Telaprevir—CTSK—Adaptive Immune System—EGFR—bone cancer	0.000119	0.00109	CbGpPWpGaD
Telaprevir—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	0.000115	0.00105	CbGpPWpGaD
Telaprevir—CTSS—Immune System—KIT—bone cancer	0.000111	0.00101	CbGpPWpGaD
Telaprevir—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	0.000109	0.000994	CbGpPWpGaD
Telaprevir—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000109	0.000991	CbGpPWpGaD
Telaprevir—ALB—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000107	0.000977	CbGpPWpGaD
Telaprevir—CTSK—Immune System—MDM2—bone cancer	0.000106	0.000968	CbGpPWpGaD
Telaprevir—CTSS—Innate Immune System—EGFR—bone cancer	0.000102	0.000936	CbGpPWpGaD
Telaprevir—CTSS—Adaptive Immune System—EGFR—bone cancer	9.84e-05	0.000899	CbGpPWpGaD
Telaprevir—CMA1—Signaling Pathways—KIT—bone cancer	9.77e-05	0.000892	CbGpPWpGaD
Telaprevir—ALB—Metabolism—NDUFA12—bone cancer	9.69e-05	0.000885	CbGpPWpGaD
Telaprevir—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	9.37e-05	0.000856	CbGpPWpGaD
Telaprevir—CTSK—Immune System—JUN—bone cancer	9.22e-05	0.000842	CbGpPWpGaD
Telaprevir—CMA1—Signaling Pathways—BRAF—bone cancer	9.18e-05	0.000838	CbGpPWpGaD
Telaprevir—ALB—Folate Metabolism—TP53—bone cancer	9.17e-05	0.000837	CbGpPWpGaD
Telaprevir—CTSS—Immune System—MDM2—bone cancer	8.73e-05	0.000798	CbGpPWpGaD
Telaprevir—ABCB1—Metabolism—NDUFA12—bone cancer	8.49e-05	0.000775	CbGpPWpGaD
Telaprevir—ALB—Hemostasis—SPARC—bone cancer	8.22e-05	0.000751	CbGpPWpGaD
Telaprevir—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	8.07e-05	0.000737	CbGpPWpGaD
Telaprevir—ALB—Metabolism—NT5C3A—bone cancer	8.03e-05	0.000733	CbGpPWpGaD
Telaprevir—CMA1—Signaling Pathways—MDM2—bone cancer	7.69e-05	0.000703	CbGpPWpGaD
Telaprevir—CTSS—Immune System—JUN—bone cancer	7.59e-05	0.000693	CbGpPWpGaD
Telaprevir—ALB—Hemostasis—GNA11—bone cancer	7.52e-05	0.000687	CbGpPWpGaD
Telaprevir—CYP3A4—Biological oxidations—GSTP1—bone cancer	7.46e-05	0.000681	CbGpPWpGaD
Telaprevir—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	7.36e-05	0.000672	CbGpPWpGaD
Telaprevir—CTSK—Immune System—EGFR—bone cancer	7.25e-05	0.000662	CbGpPWpGaD
Telaprevir—ABCB1—Metabolism—NT5C3A—bone cancer	7.03e-05	0.000642	CbGpPWpGaD
Telaprevir—ALB—Hemostasis—IL3—bone cancer	6.82e-05	0.000622	CbGpPWpGaD
Telaprevir—CMA1—Signaling Pathways—JUN—bone cancer	6.69e-05	0.000611	CbGpPWpGaD
Telaprevir—CMA1—Signaling Pathways—MMP9—bone cancer	6.51e-05	0.000594	CbGpPWpGaD
Telaprevir—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	5.99e-05	0.000547	CbGpPWpGaD
Telaprevir—CTSS—Immune System—EGFR—bone cancer	5.97e-05	0.000545	CbGpPWpGaD
Telaprevir—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	5.77e-05	0.000527	CbGpPWpGaD
Telaprevir—CMA1—Signaling Pathways—EGFR—bone cancer	5.26e-05	0.00048	CbGpPWpGaD
Telaprevir—CYP3A4—Metabolism—NDUFA12—bone cancer	5.23e-05	0.000478	CbGpPWpGaD
Telaprevir—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	5.2e-05	0.000475	CbGpPWpGaD
Telaprevir—ALB—Hemostasis—PLAU—bone cancer	4.47e-05	0.000408	CbGpPWpGaD
Telaprevir—CMA1—Signaling Pathways—TP53—bone cancer	4.41e-05	0.000403	CbGpPWpGaD
Telaprevir—CYP3A4—Metabolism—NT5C3A—bone cancer	4.33e-05	0.000396	CbGpPWpGaD
Telaprevir—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	4.09e-05	0.000373	CbGpPWpGaD
Telaprevir—ALB—Metabolism—ENO2—bone cancer	3.52e-05	0.000321	CbGpPWpGaD
Telaprevir—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	3.43e-05	0.000314	CbGpPWpGaD
Telaprevir—ALB—Metabolism—DHFR—bone cancer	3.26e-05	0.000298	CbGpPWpGaD
Telaprevir—ABCB1—Metabolism—ENO2—bone cancer	3.08e-05	0.000281	CbGpPWpGaD
Telaprevir—ALB—Metabolism—GNA11—bone cancer	3.05e-05	0.000278	CbGpPWpGaD
Telaprevir—ABCB1—Metabolism—DHFR—bone cancer	2.86e-05	0.000261	CbGpPWpGaD
Telaprevir—ALB—Metabolism—CYP3A4—bone cancer	2.76e-05	0.000252	CbGpPWpGaD
Telaprevir—ALB—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.75e-05	0.000251	CbGpPWpGaD
Telaprevir—ABCB1—Metabolism—GNA11—bone cancer	2.67e-05	0.000244	CbGpPWpGaD
Telaprevir—ABCB1—Metabolism—CYP3A4—bone cancer	2.42e-05	0.000221	CbGpPWpGaD
Telaprevir—ALB—Metabolism—GSTP1—bone cancer	2.36e-05	0.000216	CbGpPWpGaD
Telaprevir—ABCB1—Metabolism—GSTP1—bone cancer	2.07e-05	0.000189	CbGpPWpGaD
Telaprevir—CYP3A4—Metabolism—ENO2—bone cancer	1.9e-05	0.000173	CbGpPWpGaD
Telaprevir—ALB—Hemostasis—TP53—bone cancer	1.8e-05	0.000164	CbGpPWpGaD
Telaprevir—CYP3A4—Metabolism—DHFR—bone cancer	1.76e-05	0.000161	CbGpPWpGaD
Telaprevir—CYP3A4—Metabolism—GNA11—bone cancer	1.65e-05	0.00015	CbGpPWpGaD
Telaprevir—CYP3A4—Metabolism—GSTP1—bone cancer	1.28e-05	0.000117	CbGpPWpGaD
Telaprevir—ALB—Metabolism—PTGS2—bone cancer	1.22e-05	0.000112	CbGpPWpGaD
Telaprevir—ABCB1—Metabolism—PTGS2—bone cancer	1.07e-05	9.8e-05	CbGpPWpGaD
Telaprevir—CYP3A4—Metabolism—PTGS2—bone cancer	6.61e-06	6.04e-05	CbGpPWpGaD
